Molecular Products Co.


Call Us Now:


pHTN HaloTag® CMV-neo Vector

Please Enquire


Catalog number: G7721

N-Terminal Vector for Traditional Cloning

The pHTN HaloTag® CMV-neo Vector is configured to append the HaloTag® tag to the amino-terminus of the fused protein. The vector provides constitutive high-level protein expression in mammalian cells using the human cytomegalovirus (CMV) immediate-early enhancer/promoter. The vector contains a multiple cloning region for convenient cloning, and can be used for both transient and stable gene expression. The stable expression is mediated by co-expression of the neomycin phosphotransferase gene, which confers resistance to the antibiotic G-418 (Cat.# V7981). Alternatively, the HaloTag® coding region and the accompanying linker can be removed (either using PCR or restriction enzyme digestion) and transferred into other commercially available vectors.

GenBank® Accession Number and Sequence Information

pHTN HaloTag® CMV-neo GenBank® Accession Number JF920304; pHTN HaloTag® CMV-neo Vector sequence text file.


Complete Protocol

pHTN HaloTag® CMV-neo Vector Product Information

[ts-heading h2=”Specifications” txt_align=”center” css_animation=”fadeInUp”][/ts-heading]

What’s in the box?
Size: 20µg

Item Part # Size
pHTN HaloTag® CMV-neo Vector G772A 1 × 20μg

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions


Patents and Disclaimers

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the researcher is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund. Researchers may use this product for research use only, no commercial use is allowed. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the HaloTag® gene. Researchers may however clone heterologous DNA sequences at either or both ends of said HaloTag® gene so as to create fused gene sequences provided that the coding sequence of the resulting HaloTag® gene has no more than four (4) deoxynucleotides missing at the affected terminus when compared to the intact HaloTag® gene sequence. In addition, researchers must do one of the following in conjunction with use of the product: (1) use Promega HaloTag® ligands, which can be modified or linked to Promega or customer-supplied moieties, or (2) contact Promega to obtain a license if Promega HaloTag® ligands are not to be used. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

U.S. Pat. Nos. 7,425,436, 7,935,803, 8,466,269, 8,742,086, 8,420,367, 8,748,148, 9,416,353, 9,593,316 and other patents and patents pending.